VEGFA and glioblastoma: These tumours are highly angiogenic with elevated levels of vascular endothelial growth factor (VEGF) however two large randomised trials have failed to demonstrate an overall survival benefit of VEGF blockade by Bevacizumab (BEV) in the adjuvant therapy of patients with newly diagnosed GBM [3, 4].